ALL-REMOTE COMPANY/WILMINGTON, Del. / Apr 29, 2025 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”) today announced that it will release its fiscal first quarter 2026 financial results after the close of market trading on Wednesday, May 28, 2025. Phreesia will issue a press release announcing its quarterly results and the company’s quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day.
To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
ABOUT PHREESIA
Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024—1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
| Last Trade: | US$16.05 |
| Daily Change: | 0.01 0.06 |
| Daily Volume: | 886,803 |
| Market Cap: | US$961.560M |
December 08, 2025 September 04, 2025 September 04, 2025 September 02, 2025 May 28, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load